Effects of sceptical priors on the performance of adaptive clinical trials with binary outcomes.
Pharmaceutical Statistics · 2024
DOI: 10.1002/pst.2387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Anders Granholm und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care 4131, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Bayes Theorem, Research Design, Adaptive Clinical Trials as Topic, Computer Simulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Sygeforsikringen "danmark".
Abstract (Originalsprache)
It is unclear how sceptical priors impact adaptive trials. We assessed the influence of priors expressing a spectrum of scepticism on the performance of several Bayesian, multi‐stage, adaptive clinical trial designs using binary outcomes under different clinical scenarios. Simulations were conducted using fixed stopping rules and stopping rules calibrated to keep type 1 error rates at approximately 5%. We assessed total sample sizes, event rates, event counts, probabilities of conclusiveness and selecting the best arm, root mean squared errors (RMSEs) of the estimated treatment effect in the selected arms, and ideal design percentages (IDPs; which combines arm selection probabilities, power, and consequences of selecting inferior arms), with RMSEs and IDPs estimated in conclusive trials only and after selecting the control arm in inconclusive trials. Using fixed stopping rules, increasingly sceptical priors led to larger sample sizes, more events, higher IDPs in simulations ending in superiority, and lower RMSEs, lower probabilities of conclusiveness/selecting the best arm, and lower IDPs when selecting controls in inconclusive simulations. With calibrated stopping rules, the effects of increased scepticism on sample sizes and event counts were attenuated, and increased scepticism increased the probabilities of conclusiveness/selecting the best arm and IDPs when selecting controls in inconclusive simulations without substantially increasing sample sizes. Results from trial designs with gentle adaptation and non‐informative priors resembled those from designs with more aggressive adaptation using weakly‐to‐moderately sceptical priors. In conclusion, the use of somewhat sceptical priors in adaptive trial designs with binary outcomes seems reasonable when considering multiple performance metrics simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Intensive Care 4131, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Clinical Trials Methods and Outcomes Lab, PAIR (Palliative and Advanced Illness Research) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
ORCID-Profile: Anders Granholm, Theis Lange, Michael O Harhay, Anders Perner, Morten Hylander Møller, Benjamin Skov Kaas-Hansen
Förderung
- NHLBI NIH HHS
- Sygeforsikringen "danmark"
Zitieren
APA
Granholm, A., Lange, T., Harhay, M. O., Perner, A., Møller, M. H., & Kaas-Hansen, B. S. (2024). Effects of sceptical priors on the performance of adaptive clinical trials with binary outcomes. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2387
Vancouver
Granholm A, Lange T, Harhay MO, Perner A, Møller MH, Kaas-Hansen BS. Effects of sceptical priors on the performance of adaptive clinical trials with binary outcomes. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2387
BibTeX
@article{Granholm2024,
author = {Granholm, Anders and Lange, Theis and Harhay, Michael O and Perner, Anders and Møller, Morten Hylander and Kaas-Hansen, Benjamin Skov},
title = {Effects of sceptical priors on the performance of adaptive clinical trials with binary outcomes},
journal = {Pharmaceutical Statistics},
year = {2024},
doi = {10.1002/pst.2387}
}
EUVIMED